title: How HIV treatment could result in effective prevention.
abstract: As the number of HIV infections continues to surpass treatment capacity, new HIV prevention strategies are imperative. Beyond individual clinical benefits, by rendering an individual less infectious, expanding access to highly active antiretroviral therapy (HAART) could also have a larger public health impact of curbing new HIV infections. Recent guidelines have moved towards initiating HAART at higher CD4 cell counts, thus increasing the number of individuals in need of treatment. A new treatment strategy is wanting that can simultaneously curb the epidemic and provide necessary treatment to those most in need. A recent debate has centered on whether an expansion of free and universal treatment, regardless of CD4 cell count, could be a means of HIV prevention. In light of the growing access to HAART in resource-limited settings and increasing evidence suggesting the clinical and prevention benefits of initiating treatment at higher CD4 cell counts, it is conceivable that, in the future, HAART will be an integral part of both individual-level clinical treatment programs as well as public health-based HIV prevention interventions.
authors.affiliation: Department of Community Health, Division of Infectious Diseases, Department of Medicine, Alpert Medical School, Brown University/Miriam Hospital, RI, USA.
authors.forename: Kartik K
authors.initials: KK
authors.lastname: Venkatesh
authors.forename: Mark N
authors.initials: MN
authors.lastname: Lurie
authors.forename: Kenneth H
authors.initials: KH
authors.lastname: Mayer
references.citation: N Engl J Med. 1998 Mar 26;338(13):853-60
references.pmid: 9516219
references.citation: J Infect Dis. 2008 Jul 1;198(1):59-67
references.pmid: 18498241
references.citation: Lancet. 2009 Sep 19;374(9694):1023-1031
references.pmid: 19709737
references.citation: Curr Opin HIV AIDS. 2009 Jul;4(4):279-87
references.pmid: 19532065
references.citation: Trans R Soc Trop Med Hyg. 2008 Apr;102(4):310-1
references.pmid: 18316103
references.citation: J Infect Dis. 2006 Sep 15;194(6):734-9
references.pmid: 16941338
references.citation: Clin Infect Dis. 2006 Oct 1;43(7):939-41
references.pmid: 16941380
references.citation: CMAJ. 2008 Jul 1;179(1):13-4
references.pmid: 18591515
references.citation: Clin Infect Dis. 2006 Feb 1;42(3):383-4
references.pmid: 16392085
references.citation: J Acquir Immune Defic Syndr. 2006 Apr 15;41(5):632-41
references.pmid: 16652038
references.citation: N Engl J Med. 2003 May 1;348(18):1806-9
references.pmid: 12724489
references.citation: Lancet. 2009 Sep 5;374(9692):817-34
references.pmid: 19709728
references.citation: AIDS. 2003 Sep 5;17(13):1995-7
references.pmid: 12960837
references.citation: N Engl J Med. 2009 Apr 30;360(18):1815-26
references.pmid: 19339714
references.citation: AIDS. 2006 Jan 2;20(1):85-92
references.pmid: 16327323
references.citation: JAMA. 2008 Aug 6;300(5):555-70
references.pmid: 18677028
references.citation: J Infect Dis. 2005 May 1;191(9):1403-9
references.pmid: 15809897
references.citation: Clin Infect Dis. 2005 Jul 15;41(2):217-24
references.pmid: 15983918
references.citation: Lancet. 2008 Jul 26;372(9635):270-1
references.pmid: 18657692
references.citation: Clin Infect Dis. 2008 Dec 15;47(12):1580-6
references.pmid: 18990069
references.citation: AIDS. 2008 Sep;22 Suppl 3:S7-12
references.pmid: 18845925
references.citation: Emerg Themes Epidemiol. 2005 Sep 10;2:9
references.pmid: 16153307
references.citation: Lancet. 2008 May 10;371(9624):1603-11
references.pmid: 18468544
references.citation: J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):183-92
references.pmid: 17414934
references.citation: AIDS Res Hum Retroviruses. 2005 May;21(5):343-57
references.pmid: 15929696
references.citation: Am J Public Health. 2002 Mar;92(3):388-94
references.pmid: 11867317
references.citation: Bull World Health Organ. 2007 Feb;85(2):152-5
references.pmid: 17308737
references.citation: AIDS. 2001 Jan 26;15(2):143-52
references.pmid: 11216921
references.citation: Science. 2008 Jul 25;321(5888):512-9
references.pmid: 18653876
references.citation: Lancet. 2002 Jun 15;359(9323):2059-64
references.pmid: 12086758
references.citation: AIDS. 2010 Mar 13;24(5):729-35
references.pmid: 20154580
references.citation: Clin Infect Dis. 2007 Feb 1;44(3):441-6
references.pmid: 17205456
references.citation: Ann Intern Med. 2003 Apr 15;138(8):680-1
references.pmid: 12693893
references.citation: J Infect Dis. 2007 Apr 1;195(7):951-9
references.pmid: 17330784
references.citation: AIDS. 2007 Jul;21 Suppl 4:S11-20
references.pmid: 17620746
references.citation: Arch Intern Med. 1994 Sep 12;154(17):1971-6
references.pmid: 8074601
references.citation: J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):27-35
references.pmid: 17971714
references.citation: Lancet. 2001 Aug 4;358(9279):404-9
references.pmid: 11502340
references.citation: AIDS. 2007 Jul;21 Suppl 4:S117-28
references.pmid: 17620747
references.citation: Health Policy. 2003 Apr;64(1):13-37
references.pmid: 12644326
references.citation: Ann Intern Med. 2007 Apr 17;146(8):591-601
references.pmid: 17438318
references.citation: Lancet Infect Dis. 2002 Aug;2(8):487-93
references.pmid: 12150848
references.citation: AIDS. 2008 Mar 12;22(5):617-24
references.pmid: 18317003
references.citation: J Infect Dis. 2008 May 15;197 Suppl 3:S252-60
references.pmid: 18447611
references.citation: Clin Infect Dis. 2002 May 15;34(10):1391-5
references.pmid: 11981736
references.citation: J Infect Dis. 2006 Sep 15;194(6):725-33
references.pmid: 16941337
references.citation: Antivir Ther. 2008;13 Suppl 2:1-13
references.pmid: 18578063
references.citation: Lancet. 2009 Jan 3;373(9657):7-9
references.pmid: 19038440
references.citation: Am J Public Health. 2001 Jul;91(7):1060-8
references.pmid: 11441732
references.citation: N Engl J Med. 2001 Mar 15;344(11):824-31
references.pmid: 11248160
references.citation: N Engl J Med. 1997 Nov 20;337(21):1485-90
references.pmid: 9366579
references.citation: AIDS. 2006 Mar 21;20(5):653-6
references.pmid: 16514294
references.citation: J Infect Dis. 2004 Sep 1;190(5):879-85
references.pmid: 15295691
references.citation: Lancet. 2009 Jan 3;373(9657):48-57
references.pmid: 19038438
references.citation: J Infect Dis. 2003 Feb 15;187(4):683-6
references.pmid: 12599087
references.citation: Sex Transm Dis. 2008 Dec;35(12):1009-10
references.pmid: 18936724
references.citation: Lancet. 2000 Jun 17;355(9221):2147-52
references.pmid: 10902643
references.citation: Am J Public Health. 2005 Jan;95(1):18-22
references.pmid: 15623853
references.citation: Lancet. 2003 Sep 13;362(9387):859-68
references.pmid: 13678973
references.citation: AIDS. 2008 Jul 11;22(11):1305-12
references.pmid: 18580610
references.citation: AIDS. 2007 May 11;21(8):965-71
references.pmid: 17457090
references.citation: Lancet. 2006 Aug 5;368(9534):505-10
references.pmid: 16890837
references.citation: JAMA. 2004 Jul 14;292(2):224-36
references.pmid: 15249572
references.citation: AIDS. 2007 Jul;21 Suppl 4:S55-63
references.pmid: 17620754
references.citation: Int J Tuberc Lung Dis. 2005 Oct;9(10):1062-71
references.pmid: 16229216
references.citation: Clin Infect Dis. 2010 Feb 1;50(3):416-25
references.pmid: 20043752
references.citation: Lancet Infect Dis. 2009 Oct;9(10):637-49
references.pmid: 19778766
references.citation: J Acquir Immune Defic Syndr. 2002 Mar 1;29(3):275-83
references.pmid: 11873077
references.citation: N Engl J Med. 2010 Mar 18;362(11):967-70
references.pmid: 20147707
references.citation: HIV Med. 2006 Oct;7(7):442-50
references.pmid: 16925730
references.citation: AIDS. 2007 May 31;21(9):1185-97
references.pmid: 17502729
references.citation: Lancet. 2006 Mar 11;367(9513):817-24
references.pmid: 16530575
references.citation: Antivir Ther. 2007;12(4):543-51
references.pmid: 17668563
references.citation: N Engl J Med. 2000 Mar 30;342(13):921-9
references.pmid: 10738050
references.citation: Lancet. 2006 Jun 3;367(9525):1870-2
references.pmid: 16753490
references.citation: Ann Intern Med. 2000 Jul 4;133(1):21-30
references.pmid: 10877736
references.citation: Ann Intern Med. 2009 Aug 4;151(3):157-66
references.pmid: 19620143
references.citation: Lancet. 2006 Aug 5;368(9534):531-6
references.pmid: 16890841
references.citation: J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):96-101
references.pmid: 16123689
references.citation: AIDS Patient Care STDS. 2008 Apr;22(4):337-44
references.pmid: 18422462
references.citation: J Infect Dis. 2004 May 15;189(10):1785-92
references.pmid: 15122514
references.citation: AIDS. 2008 Jan 2;22(1):107-13
references.pmid: 18090398
references.citation: N Engl J Med. 2006 Sep 14;355(11):1141-53
references.pmid: 16971720
references.citation: J Infect Dis. 2006 Jul 1;194(1):11-9
references.pmid: 16741877
references.citation: AIDS. 1997 Aug;11(10):1249-54
references.pmid: 9256943
references.citation: Antivir Ther. 2004 Jun;9(3):375-84
references.pmid: 15259900
references.citation: J Acquir Immune Defic Syndr. 2008 Nov 1;49(3):287-93
references.pmid: 18845953
references.citation: J Acquir Immune Defic Syndr. 2009 Nov;52 Suppl 1:S49-51
references.pmid: 19858939
references.citation: Lancet. 2007 Aug 4;370(9585):407-13
references.pmid: 17659333
references.citation: AIDS. 2000 Mar 10;14(4):415-21
references.pmid: 10770544
references.citation: JAMA. 2006 Aug 9;296(6):679-90
references.pmid: 16896111
references.citation: JAMA. 2010 May 12;303(18):1798-9
references.pmid: 20460611